148291-65-0 Usage
General Description
(E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid is a complex chemical compound that consists of a xanthene core with a carboxylic acid group at one end and a propanoic acid group at the other. It also contains a hexenyl oxy and a methoxyphenyl substituent. (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene -4-propanoic acid has potential applications in pharmaceuticals, as xanthene derivatives have been found to have anti-inflammatory, antioxidant, and antimicrobial properties. The presence of the methoxy group may also contribute to its potential as a drug candidate, as methoxy groups are known to enhance the bioavailability and pharmacokinetics of a compound. Additional research is needed to fully understand the potential uses and effects of this complex chemical compound.
Check Digit Verification of cas no
The CAS Registry Mumber 148291-65-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,2,9 and 1 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 148291-65:
(8*1)+(7*4)+(6*8)+(5*2)+(4*9)+(3*1)+(2*6)+(1*5)=150
150 % 10 = 0
So 148291-65-0 is a valid CAS Registry Number.
InChI:InChI=1/C30H28O8/c1-36-21-10-7-19(8-11-21)6-4-2-3-5-17-37-25-15-12-23-28(33)24-18-20(30(34)35)9-14-26(24)38-29(23)22(25)13-16-27(31)32/h4,6-12,14-15,18H,2-3,5,13,16-17H2,1H3,(H,31,32)(H,34,35)/b6-4+
148291-65-0Relevant articles and documents
Design, Synthesis, and Pharmacological Evaluation of Potent Xanthone Dicarboxylic Acid Leukotriene B4 Receptor Antagonists
Jackson, William T.,Boyd, Robert J.,Froelich, Larry L.,Gapinski, D. Mark,Mallett, Barbara E.,Sawyer, J. Scott
, p. 1726 - 1734 (2007/10/02)
In an effort to develop increasingly potent and specific leukotriene B4(LTB4) receptor antagonists, several xanthone dicarboxylic acids were synthesized and evaluated.Two separate synthetic routes were used to construct a xanthone nucleus containing a regiospecific orientation of each carboxylic acid pharmacophore.These compounds represent the major conformationally-restricted analogues of benzophenone dicarboxylic acids previously shown to antagonize the activation of human neutrophils by LTB4.The most potent agent was compound 32, which inhibited the specific binding of LTB4 to receptors on intact human neutrophils (IC50, 6.2 +/- 0.1 nM), LTB4-induced luminol-dependent chemiluminescence (IC50, 55 +/- 11 nM), aggregation (IC50, 133 +/- 42 nM), and chemotaxis (IC50, 899 +/- 176 nM).The compound was a poor antagonist of N-formyl-L-methionyl-L-leucyl-L-phenylalanine-induced chemiluminescence (IC50, 1599 +/- 317 nM) and aggregation (IC50, 2166 +/- 432 nM), indicating specificity in the inhibition of LTB4-stimulated events.Compound 32(LY210073), which was completely devoid of agonist activity, appears to be one of the strongest inhibitors of LTB4 receptor binding reported so far.
